Katherine L. Lee

Discovery of Clinical Candidate 1-{[(2 <i>S</i> ,3 <i>S</i> ,4 <i>S</i> )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

Katherine L. Lee, Catherine M. Ambler, David R. Anderson et al. · Journal of Medicinal Chemistry · 2017 · 138 citations · Full text

Indole Cytosolic Phospholipase A₂α Inhibitors: Discovery and in Vitro and in Vivo Characterization of 4-{3-[5-Chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1<i>H</i>-indol-3-yl]propyl}benzoic Acid, Efipladib

John C. McKew, Katherine L. Lee, Marina W. H. Shen et al. · Journal of Medicinal Chemistry · 2008 · 88 citations

The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists

Stefan Vollmer, Sam Strickson, Tinghu Zhang et al. · Biochemical Journal · 2017 · 80 citations · Full text

Blockade of cytosolic phospholipase A2α prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses

Suzana Marušić, Paresh Thakker, Jeffrey W. Pelker et al. · Journal of Neuroimmunology · 2008 · 55 citations

Inflammation, Autoimmune Disease, Immune Cell Development +14

Novel entry to the Ergot alkaloids via ring closing metathesis

Katherine L. Lee, Jane Betty Goh, Stephen F. Martin · Tetrahedron Letters · 2001 · 35 citations

Ergot Alkaloids, Biochemistry, Medicine +5